MEK and BRD4 inhibitors induce cell death of subset of KRAS-mutant lung tumors in vitro and in vivo

ChEBI2021-09-02 更新2026-07-12 收录

KRAS突变治疗

肿瘤药物临床前评估

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-MTAB-7180 数据链接链接失效反馈

官方服务：

资源简介：

MEK and BRD4 inhibitors induce cell death of subset of KRAS-mutant lung tumors in vitro and in vivo

创建时间：

2021-09-02

Expression data from tumor lungs after continuous vs. pulsatile selumetinib treatment in KRASG12C GEMM. Expression data from tumor lungs after continuous vs. pulsatile selumetinib treatment in KRASG12C GEMM

KRAS突变治疗

MEK激酶

KRAS is one of the driver oncogenes in non-small cell lung cancer (NSCLC), but remains refractory to current modalities of targeted pathway inhibition, which include inhibiting downstream kinase MEK t

NIAID Data Ecosystem50

Effectiveness of irinotecan plus trabectedin in a desmoplastic small round cell tumor patient-derived xenograft

肿瘤药物临床前评估

癌症靶向治疗

Desmoplastic small round cell tumor (DSRCT) is a rare and incurable malignancy characterized by the oncogenic EWSR1-WT1 transcription factor. This study exploited a novel DSRCT patient-derived xenogra

NIAID Data Ecosystem30

MEK Inhibitor Trametinib combined with RTK Inhibitor Anlotinib in KRAS-Mutant Lung Cancer

KRAS突变治疗

药物联合疗法

Oncogenic KRAS mutations frequently detected in non-small cell lung cancer (NSCLC) have been considered undruggable until recent development of inhibitors, e.g., sortorasib, adagrasib or divarasib, sp

NIAID Data Ecosystem10

A ‘Synthetic-Sickness’ Screen for Senescence Re-engagement Targets in Mutant Cancer Backgrounds. Homo sapiens

细胞衰老诱导

KRAS突变治疗

Senescence is a universal barrier to immortalisation and tumorigenesis. As such, interest in the use of senescence-induction in a therapeutic context has been gaining momentum in the past few years; h

NIAID Data Ecosystem50

Study of Cetuximab + Irinotecan + S-1 as first line therapy in metastatic colorectal cancer with KRAS wild type

KRAS突变治疗

西妥昔单抗联合化疗

Interventions: IRIS + Cetuximab Cetuximab loading dose 400mg/m2, 250 mg/m2/week Irinotecan 100 mg/m2/biweekly S-1 80,100,120 mg/twice/day 1-14, following two weeks off Primary outcome(s): Response Rat

NIAID Data Ecosystem20

MEK and BRD4 inhibitors induce cell death of subset of KRAS-mutant lung tumors in vitro and in vivo

资源简介：

相关数据集